Imaging of brain tumors: Perfusion/permeability

Neuroimaging Clinics of North America

Volumn 20, Issue 3, 2010, Pages 337-353

  Thompson, Gerard ^a   Mills, Samantha Jane ^a   Stivaros, Stavros Michael ^a   Jackson, Alan ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Brain tumor; Dynamic imaging; Glioma; Perfusion; Permeability

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; CARBOPLATIN; CEDIRANIB; TEMOZOLOMIDE; THALIDOMIDE;

BRAIN ABSCESS; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN BLOOD VOLUME; BRAIN CANCER; BRAIN PERFUSION; CANCER CLASSIFICATION; CANCER GRADING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED MEDICINE; GLIOMA; HUMAN; IMAGE ANALYSIS; LYMPHOMA; MALIGNANT TRANSFORMATION; MEDICAL LITERATURE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; SENSITIVITY AND SPECIFICITY; SPIN LABELING; STANDARDIZATION; TREATMENT RESPONSE;

BRAIN; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; GLIOMA; HUMANS; LYMPHOMA; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; NEOVASCULARIZATION, PATHOLOGIC; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 77955569738     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2010.04.008     Document Type: Review

References (122)

1. Jackson A., Stivaros S., Moore E.A. Advances in magnetic resonance imaging. Imaging 2006, 18:97-109.
2. O'Connor J.P., Jackson A., Asselin M.C., et al. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol 2008, 9(8):766-776.
3. Herholz K., Coope D., Jackson A. Metabolic and molecular imaging in neuro-oncology. Lancet Neurol 2007, 6(8):711-724.
4. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69(3):89-95.
5. Goh V., Halligan S., Bartram C.I. Quantitative tumor perfusion assessment with multidetector CT: are measurements from two commercial software packages interchangeable?. Radiology 2007, 242(3):777-782.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):1182-1186.
7. Uematsu H., Maeda M., Sadato N., et al. Vascular permeability: quantitative measurement with double-echo dynamic MR imaging-theory and clinical application. Radiology 2000, 214(3):912-917.
8. Knopp M.V., Weiss E., Sinn H.P., et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999, 10(3):260-266.
9. Jayson G.C., Zweit J., Jackson A., et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002, 94(19):1484-1493.
10. Kassner A., Annesley D.J., Zhu X.P., et al. Abnormalities of the contrast re-circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast-enhanced imaging: a possible marker of vascular tortuosity. J Magn Reson Imaging 2000, 11(2):103-113.
11. Thacker N.A., Scott M.L., Jackson A. Can dynamic susceptibility contrast magnetic resonance imaging perfusion data be analyzed using a model based on directional flow?. J Magn Reson Imaging 2003, 17(2):241-255.
12. Jayson G.C., Parker G.J., Mullamitha S., et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005, 23(5):973-981.
13. de Langen A.J., Lubberink M., Boellaard R., et al. Reproducibility of tumor perfusion measurements using 15O-labeled water and PET. J Nucl Med 2008, 49(11):1763-1768.
14. Mullins M.E. Stroke imaging with xenon-CT. Semin Ultrasound CT MR 2006, 27(3):219-220.
15. Jackson A., Buckley D.L., Parker G.J.M. Dynamic contrast-enhanced magnetic resonance imaging in oncology 2005, Springer, Berlin.
16. Leach M.O., Brindle K.M., Evelhoch J.L., et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol 2003, 76(Spec No 1):S87-S91.
17. Golay X., Hendrikse J., Lim T.C. Perfusion imaging using arterial spin labeling. Top Magn Reson Imaging 2004, 15(1):10-27.
18. Uematsu H., Maeda M. Double-echo perfusion-weighted MR imaging: basic concepts and application in brain tumors for the assessment of tumor blood volume and vascular permeability. Eur Radiol 2006, 16(1):180-186.
19. Jackson A., Kassner A., Annesley-Williams D., et al. Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade. AJNR Am J Neuroradiol 2002, 23(1):7-14.
20. Hu L.S., Baxter L.C., Pinnaduwage D.S., et al. Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. AJNR Am J Neuroradiol 2010, 31(1):40-48.
21. Paulson E.S., Schmainda K.M. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008, 249(2):601-613.
22. * contrast-enhanced dynamic MR imaging. J Magn Reson Imaging 2000, 11(6):575-585.
23. Stack J., Redmond O., Codd M., et al. Breast disease: tissue characterization with Gd-DTPA enhancement profiles. Radiology 1990, 174:491-494.
24. Flickinger F., Allison J., Sherry R., et al. Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. Magn Reson Imaging 1993, 11:617-620.
25. Roberts C., Issa B., Stone A., et al. Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imaging 2006, 23(4):554-563.
26. St Lawrence K., Lee T. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: I. Theoretical derivation. J Cereb Blood Flow Metab 1998, 18:1365-1377.
27. Ostergaard L., Chesler D., Weisskoff R., et al. Modelling cerebral blood flow and flow heterogeneity from magnetic resonance residue data. J Cereb Blood Flow Metab 1999, 19:690-699.
28. Vallee J.P., Lazeyras F., Khan H.G., et al. Absolute renal blood flow quantification by dynamic MRI and Gd-DTPA. Eur Radiol 2000, 10(8):1245-1252.
29. Lu H., Golay X., Pekar J.J.., et al. Functional magnetic resonance imaging based on changes in vascular space occupancy. Magn Reson Med 2003, 50(2):263-274.
30. Lu H., van Zijl P.C., Hendrikse J., et al. Multiple acquisitions with global inversion cycling (MAGIC): a multislice technique for vascular-space-occupancy dependent fMRI. Magn Reson Med 2004, 51(1):9-15.
31. Donahue M.J., Blakeley J.O., Zhou J., et al. Evaluation of human brain tumor heterogeneity using multiple T1-based MRI signal weighting approaches. Magn Reson Med 2008, 59(2):336-344.
32. Lu H., Law M., Johnson G., et al. Novel approach to the measurement of absolute cerebral blood volume using vascular-space-occupancy magnetic resonance imaging. Magn Reson Med 2005, 54(6):1403-1411.
33. Lu H., Pollack E., Young R., et al. Predicting grade of cerebral glioma using vascular-space occupancy MR imaging. AJNR Am J Neuroradiol 2008, 29(2):373-378.
34. Edelman R.R., Siewert B., Adamis M., et al. Signal targeting with alternating radiofrequency (STAR) sequences: application to MR angiography. Magn Reson Med 1994, 31(2):233-238.
35. Kwong K.K., Chesler D.A., Weisskoff R.M., et al. MR perfusion studies with T1-weighted echo planar imaging. Magn Reson Med 1995, 34(6):878-887.
36. Kim H.S., Kim S.Y. A prospective study on the added value of pulsed arterial spin-labeling and apparent diffusion coefficients in the grading of gliomas. AJNR Am J Neuroradiol 2007, 28(9):1693-1699.
37. * and T1 weighted MRI data in intra-axial cerebral tumours. Br J Radiol 2007, 80(951):161-168.
38. Tofts P.S., Brix G., Buckley D.L., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10(3):223-232.
39. Tofts P.S., Kermode A.G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991, 17(2):357-367.
40. Emblem K.E., Nedregaard B., Nome T., et al. Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. Radiology 2008, 247(3):808-817.
41. Emblem K.E., Scheie D., Due-Tonnessen P., et al. Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes. AJNR Am J Neuroradiol 2008, 29(9):1664-1670.
42. Law M., Young R., Babb J., et al. Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas. AJNR Am J Neuroradiol 2007, 28(4):761-766.
43. Young R., Babb J., Law M., et al. Comparison of region-of-interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas. J Magn Reson Imaging 2007, 26(4):1053-1063.
44. Rose C.J., Mills S.J., O'Connor J.P., et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med 2009, 62(2):488-499.
45. Erdogan C., Hakyemez B., Yildirim N., et al. Brain abscess and cystic brain tumor: discrimination with dynamic susceptibility contrast perfusion-weighted MRI. J Comput Assist Tomogr 2005, 29(5):663-667.
46. Holmes T.M., Petrella J.R., Provenzale J.M. Distinction between cerebral abscesses and high-grade neoplasms by dynamic susceptibility contrast perfusion MRI. AJR Am J Roentgenol 2004, 183(5):1247-1252.
47. Bink A., Gaa J., Franz K., et al. Importance of diffusion-weighted imaging in the diagnosis of cystic brain tumors and intracerebral abscesses. Zentralbl Neurochir 2005, 66(3):119-125.
48. Mascalchi M., Filippi M., Floris R., et al. Diffusion-weighted MR of the brain: methodology and clinical application. Radiol Med (Torino) 2005, 109(3):155-197.
49. Haris M., Gupta R.K., Singh A., et al. Differentiation of infective from neoplastic brain lesions by dynamic contrast-enhanced MRI. Neuroradiology 2008, 50(6):531-540.
50. Calli C., Kitis O., Yunten N., et al. MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 2006, 58(3):394-403.
51. Lee I.H., Kim S.T., Kim H.J., et al. Analysis of perfusion weighted image of CNS lymphoma. Eur J Radiol 2009 June 3. [Online].
52. Sugahara T., Korogi Y., Shigematsu Y., et al. Value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors. Top Magn Reson Imaging 1999, 10(2):114-124.
53. Liao W., Liu Y., Wang X., et al. Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Acta Radiol 2009, 50(2):217-225.
54. Weber M.A., Zoubaa S., Schlieter M., et al. Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors. Neurology 2006, 66(12):1899-1906.
55. Strugar J.G., Criscuolo G.R., Rothbart D., et al. Vascular endothelial growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cysts. J Neurosurg 1995, 83(4):682-689.
56. Strugar J., Rothbart D., Harrington W., et al. Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis. J Neurosurg 1994, 81(4):560-566.
57. Rollin N., Guyotat J., Streichenberger N., et al. Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors. Neuroradiology 2006, 48(3):150-159.
58. Cha S., Knopp E.A., Johnson G., et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002, 223(1):11-29.
59. Cha S, Law M, Johnson G, et al. Peritumoral region: differentiation between primary high-grade neoplasma and solitary metastasis using dynamic contrast-enhanced T2*-weighted echo-planar perfusion MR imaging. In: Proceeding of the 38th Annual Meeting of the American Society of Neuroradiology. Atlanta (GA): American Society of Neuroradiology; 2000. p. 22.
60. Cha S., Lupo J.M., Chen M.H., et al. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007, 28(6):1078-1084.
61. Maeda M., Itoh S., Kimura H., et al. Vascularity of meningiomas and neuromas: assessment with dynamic susceptibility-contrasst MRF imaging. Am J Roentgenol 1994, 163(1):181-186.
62. Miyati T., Banno T., Mase M., et al. Dual dynamic contrast-enhanced MR imaging. J Magn Reson Imaging 1997, 7(1):230-235.
63. Long D.M. Vascular ultrastructure in human meningiomas and schwannomas. J Neurosurg 1973, 38(4):409-419.
64. Hakyemez B., Yildirim N., Erdogan C., et al. Meningiomas with conventional MRI findings resembling intraaxial tumors: can perfusion-weighted MRI be helpful in differentiation?. Neuroradiology 2006, 48(10):695-702.
65. Yang S., Law M., Zagzag D., et al. Dynamic contrast-enhanced perfusion MR imaging measurements of endothelial permeability: differentiation between atypical and typical meningiomas. AJNR Am J Neuroradiol 2003, 24(8):1554-1559.
66. Zhang H., Rodiger L.A., Shen T., et al. Perfusion MR imaging for differentiation of benign and malignant meningiomas. Neuroradiology 2008, 50(6):525-530.
67. Aronen H.J., Pardo F.S., Kennedy D.N., et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000, 6(6):2189-2200.
68. Aronen H.J., Gazit I.E., Louis D.N., et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994, 191(1):41-51.
69. Aronen H.J., Glass J., Pardo F.S., et al. Echo-planar MR cerebral blood volume mapping of gliomas. Clinical utility. Acta Radiol 1995, 36(5):520-528.
70. *-weighted MR imaging. Radiology 1999, 211(3):791-798.
71. Law M., Yang S., Wang H., et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003, 24(10):1989-1998.
72. Ludemann L., Grieger W., Wurm R., et al. Comparison of dynamic contrast-enhanced MRI with WHO tumor grading for gliomas. Eur Radiol 2001, 11(7):1231-1241.
73. Provenzale J.M., Wang G.R., Brenner T., et al. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 2002, 178(3):711-716.
74. Ding B., Ling H.W., Chen K.M., et al. Comparison of cerebral blood volume and permeability in preoperative grading of intracranial glioma using CT perfusion imaging. Neuroradiology 2006, 48(10):773-781.
75. Ellika S.K., Jain R., Patel S.C., et al. Role of perfusion CT in glioma grading and comparison with conventional MR imaging features. AJNR Am J Neuroradiol 2007, 28(10):1981-1987.
76. Di Costanzo A., Scarabino T., Trojsi F., et al. Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy. Neuroradiology 2006, 48(9):622-631.
77. Patankar T.F., Haroon H.A., Mills S.J., et al. Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas?. AJNR Am J Neuroradiol 2005, 26(10):2455-2465.
78. Law M., Yang S., Babb J.S., et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004, 25(5):746-755.
79. Jain R., Ellika S.K., Scarpace L., et al. Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade. AJNR Am J Neuroradiol 2008, 29(4):694-700.
80. Warmuth C., Gunther M., Zimmer C. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003, 228(2):523-532.
81. Brown G.G., Clark C., Liu T.T. Measurement of cerebral perfusion with arterial spin labeling: part 2. Applications. J Int Neuropsychol Soc 2007, 13(3):526-538.
82. Kimura H., Takeuchi H., Koshimoto Y., et al. Perfusion imaging of meningioma by using continuous arterial spin-labeling: comparison with dynamic susceptibility-weighted contrast-enhanced MR images and histopathologic features. AJNR Am J Neuroradiol 2006, 27(1):85-93.
83. Sugahara T., Korogi Y., Kochi M., et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998, 171(6):1479-1486.
84. Roberts H.C., Roberts T.P., Brasch R.C., et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000, 21(5):891-899.
85. Roberts H.C., Roberts T.P., Bollen A.W., et al. Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors. Acad Radiol 2001, 8(5):384-391.
86. Maeda M., Itoh S., Kimura H., et al. Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology 1993, 189(1):233-238.
87. Pathak A.P., Schmainda K.M., Ward B.D., et al. MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis. Magn Reson Med 2001, 46(4):735-747.
88. Sadeghi N., Salmon I., Tang B.N., et al. Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: preliminary results. J Magn Reson Imaging 2006, 24(5):989-994.
89. Roux F.X., Nataf F. Cerebral oligodendrogliomas in adults and children. Current data and perspectives. Neurochirurgie 2005, 51(3-4 Pt 2):410-414.
90. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90(19):1473-1479.
91. Xu M., See S.J., Ng W.H., et al. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 2005, 56(5):919-926. [discussion: 26].
92. White M.L., Zhang Y., Kirby P., et al. Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?. AJNR Am J Neuroradiol 2005, 26(4):784-790.
93. Lev M.H., Ozsunar Y., Henson J.W., et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004, 25(2):214-221.
94. Jenkinson M.D., Smith T.S., Joyce K.A., et al. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 2006, 48(10):703-713.
95. Law M., Brodsky J.E., Babb J., et al. High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: preliminary results of molecular studies in gliomas with elevated perfusion. J Magn Reson Imaging 2007, 25(6):1113-1119.
96. Whitmore R.G., Krejza J., Kapoor G.S., et al. Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 2007, 107(3):600-609.
97. Caseiras G.B., Chheang S., Babb J., et al. Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. Eur J Radiol 2010, 73(2):215-220.
98. Law M., Young R.J., Babb J.S., et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008, 247(2):490-498.
99. Danchaivijitr N., Waldman A.D., Tozer D.J., et al. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation?. Radiology 2008, 247(1):170-178.
100. Wong E.T., Jackson E.F., Hess K.R., et al. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology 1998, 50(3):777-781.
101. Hawighorst H., Knopp M.V., Debus J., et al. Pharmacokinetic MRI for assessment of malignant glioma response to stereotactic radiotherapy: initial results. J Magn Reson Imaging 1998, 8(4):783-788.
102. Cao Y., Tsien C.I., Nagesh V., et al. Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 2006, 64(3):876-885.
103. Chaskis C., Stadnik T., Michotte A., et al. Prognostic value of perfusion-weighted imaging in brain glioma: a prospective study. Acta Neurochir (Wien) 2006, 148(3):277-285. [discussion: 85].
104. Mills S.J., Patankar T.A., Haroon H.A., et al. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma?. AJNR Am J Neuroradiol 2006, 27(4):853-858.
105. Leimgruber A., Ostermann S., Yeon E.J., et al. Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. Int J Radiat Oncol Biol Phys 2006, 64(3):869-875.
106. Galban C.J., Chenevert T.L., Meyer C.R., et al. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 2009, 15(5):572-576.
107. Hamstra D.A., Chenevert T.L., Moffat B.A., et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 2005, 102(46):16759-16764.
108. Hamstra D.A., Galban C.J., Meyer C.R., et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008, 26(20):3387-3394.
109. Tsien C., Galban C.J., Chenevert T.L., et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol 2010, 28(13):2293-2299.
110. Narayana A., Golfinos J.G., Fischer I., et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 2008, 72(2):383-389.
111. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11(1):83-95.
112. Quarles C.C., Schmainda K.M. Assessment of the morphological and functional effects of the anti-angiogenic agent SU11657 on 9L gliosarcoma vasculature using dynamic susceptibility contrast MRI. Magn Reson Med 2007, 57(4):680-687.
113. O'Connor J.P.B., Jackson A., Parker G.J.M., et al. DCE-MRI biomarkers in the clinical evaluation of anti-angiogenic and avascular disupting agents. Br J Cancer 2007, 96:189-195.
114. Cha S., Knopp E.A., Johnson G., et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000, 21(5):881-890.
115. Laperriere N., Zuraw L., Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002, 64(3):259-273.
116. Alavi J.B., Alavi A., Chawluk J., et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988, 62(6):1074-1078.
117. Rosen B.R., Belliveau J.W., Aronen H.J., et al. Susceptibility contrast imaging of cerebral blood volume: human experience. Magn Reson Med 1991, 22(2):293-299.
118. Boxerman J., Hamberg L., Rosen B., et al. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995, 34:555-566.
119. Reinhold H.S., Endrich B. Tumour microcirculation as a target for hyperthermia. Int J Hyperthermia 1986, 2(2):111-137.
120. Hu L.S., Baxter L.C., Smith K.A., et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009, 30(3):552-558.
121. Gobbel G.T., Seilhan T.M., Fike J.R. Cerebrovascular response after interstitial irradiation. Radiat Res 1992, 130(2):236-240.
122. Hein P.A., Eskey C.J., Dunn J.F., et al. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 2004, 25(2):201-209.